E2F3 and non-small cell lung carcinoma: Taken together, these results suggest that potent, specific activator E2F inhibition may be useful in the treatment of NSCLC in the future (especially in combination with other agents), and that E2F3 levels may be a good predictor of paclitaxel sensitivity in NSCLC.